The rise of GLP-1 agonist drugs in Type 2 diabetes and anti-obesity
This table reflects the general shape of a titration curve rather than a fixed protocol, since every patients schedule is individualized by their provider based on how they respond at each stage
A medication that can resolve steatosis in 90%+ of patients represents a potential paradigm shift in hepatology
Abstracts, reviews, editorials, and other articles without original data were also excluded
Key takeaways Ozempic and Jardiance are FDA approved to treat Type 2 diabetes but differ in mechanism of action, active ingredients, dosage forms, and side effects
106 Two additional clinical trials are being conducted to gather more data on adverse effects in different situations of liver injury, and a phase 2 trial investigating treatment effects for MASH with fibrosis based on histological assessment is ongoing (NCT05877547)